Navigation Links
SNM applauds FDA's decision to approve Zevalin
Date:9/10/2009

RESTON, Va.SNM applauds the U.S. Food and Drug Administration's (FDA) recent decision to approve the radioimmunotherapy (RIT) drug, Zevalin, as a front-line treatment of non-Hodgkin's lymphoma (NHL).

"This is welcome news for patients with non-Hodgkin's lymphoma," said Michael M. Graham, M.D., Ph.D., president of SNM and director of nuclear medicine at the University of Iowa Carver College of Medicine. "We've known for some time that RIT works extremely well for many NHL patients. With the FDA's approval, more patients can take advantage of this promising treatment sooner rather than later, giving them more hope for a brighter future."

This is the first time that the drug has been approved as an effective treatment option at the time of onset of lymphoma. Previously, Zevalin was approved only to treat lymphoma after a relapse, or after all conventional therapies failed. Now, patients with NHL can reap the same benefits earlier on in the disease, before it progresses to a more serious stage.

Non-Hodgkin's lymphomaone of the two main types of lymphomahas many different forms and is the fifth most common cancer in the United States. When lymphoma is first diagnosed, treatment choices depend on the cell type, extent of disease and rate of progression. New and emerging molecular imaging therapies, such as RIT, continue to provide major breakthroughs for patients with NHL by allowing tailored treatments at the molecular level. RIT is a more highly targeted therapy than traditional treatments because molecular imaging techniques and therapies can pinpoint the exact location of disease and deliver a tumor-killing dose of a radioactive substance directly to the cancer cells while sparing healthy cells.

"New developments in molecular imaging technologies are dramatically improving the ways in which lymphoma is diagnosed and treated," says Peter S. Conti, M.D., Ph.D., professor of radiology, clinical pharmacy and biomedical engineering at the University of Southern California's Keck School of Medicine. "Research in molecular imaging is also contributing to our understanding of lymphoma and helping to direct more effective care of patients with the disease."


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. National Alliance for Hispanic Health Applauds President Obamas Efforts to Achieve Meaningful Health Care Reform in 2009
2. The American Heart Association Applauds Recommendations in New Childhood Obesity Report
3. HIMSS Electronic Health Record Association Applauds Federal Support of EHR Implementation for Hospitals and Physician Practices
4. NABP Applauds LegitScript and KnujOn for Spotlighting Exploitation of Internet Ad Programs by Rogue Internet Drug Outlets
5. Americans United for Life Applauds Decision Protecting Women From Dangers of RU-486
6. The Lupus Foundation of America Applauds New Legislation that Caps Out-of-Pocket Drug Costs
7. National Alliance for Hispanic Health Applauds Confirmation of Sonia Sotomayor as the Nations 111th Supreme Court Justice
8. The Scleroderma Foundation Applauds Introduction of First Bill in the Senate Promoting Research and Awareness of Scleroderma
9. GMA Applauds U.S. House for Passage of Landmark Food Safety Bill
10. Partnership Applauds Obamas No Cost-Sharing Protections for Preventive Services
11. APHA Applauds Congressional Action on Health Reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... 27, 2017 , ... Healthcare companies are trying to meet talent shortages and ... healthcare executive resume. , “If you’re a healthcare executive open to new opportunities this ... it’s as ready as you are for a new job search. I’ve heard from ...
(Date:4/27/2017)... ... 27, 2017 , ... The American Brain Foundation last night ... Neurology Award (PLINA). The couple joins a prestigious list of past PLINA winners, ... actor Michael J. Fox and former U.S. Attorney General Janet Reno. , Smith ...
(Date:4/27/2017)... ... April 27, 2017 , ... SyncDog, Inc. ... at MobileIron Live! 2017 in Santa Clara, California. Each year, MobileIron ... approach to helping organizations maximize the benefits of mobility in their operations securely. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its kind, Swissx ... and more potent than the market has seen before. Swissx uses proprietary strains of ... a patented chromatography process for extraction, to produce its CBD oil--maximizing its benefits for ...
(Date:4/27/2017)... CA (PRWEB) , ... April 27, 2017 , ... Plastic ... MD , have been asked to present at the upcoming Aesthetic Meeting. Held in ... April 27-May 2. Drs. Furnas and Canales will lend their expertise to the Premier ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/18/2017)... 2017  Cardinal Health (NYSE: CAH ) ... earnings per share (EPS) guidance and providing a preliminary ... conjunction with this morning,s announcement of the planned acquisition ... Insufficiency businesses. Cardinal Health now believes that ... at the bottom of its previous guidance range of ...
(Date:4/18/2017)... April 18, 2017  Astute Medical, Inc., developer of ... to be presented at the 2017 National Kidney Foundation ... and continues through April 22. Physicians will present data ... to assess risk for acute kidney injury (AKI) during ... (ADHF). Elevated levels of TIMP-2 and ...
Breaking Medicine Technology: